Lupin has announced the launch of the authorised generic version of Antara (Fenofibrate) capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, S.A. Corporation, a wholly-owned subsidiary of Lupin.

Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides rrG) and apolopoprotein B (Apo B), and to increase high-density fipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.

Fenofibrate Capsules (RLD: Antara capsules) had estimated annual sales of US $ 7 million in the U.S. (IQVIA MAT September 2021).